Company intelligence / Profile preview

Thabor Therapeutics

Paris, Île-de-France, Francethabor-tx.com ↗

Ownership: Private
Employees: ~10
Development stage: Preclinical

Overview

Thabor Therapeutics, an INSERM spin-off based in Paris, France, develops a first-in-class therapeutic antibody targeting extracellular AGR2 for the treatment of chronic mucosal inflammatory diseases. Their approach aims to reinstate epithelial homeostasis by blocking the initial stress signal from the epithelium, thereby preventing inflammation and fibrosis without immunosuppression. The company’s lead program appears preclinical with no reported clinical results yet.

Therapeutic areas: Immunology
Modalities: monoclonal antibodies (therapeutic antibody)
Industry: Biotech

Drug pipeline

1 asset

anti-eAGR2 monoclonal antibody (Thabor Therapeutics)

Preclinical

Partnerships

INSERM (spin-off origin); no major pharma partnerships disclosed

Beyond the preview

Go deeper on Thabor Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Thabor Therapeutics.

Explore the full profile